A Phase 2 interventional study of Colchicine 0.5 MG Oral Tablet and Placebo in Type 1 Diabetes, Cardiovascular Diseases and Chronic Inflammation, sponsored by Asger Lund, MD. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Asger Lund, MD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 45th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2023, is one of 16 in phase 2, reaches primary completion later than 33 of the 34 other live ones, and was the 160th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 2–18
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Klavs Würgler Hansen · Sites in Denmark
Ages 18+
Henrik Bo Wiberg Larsson · Sites in Denmark, Germany
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 34 · Phase 4 19
First in 1995; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 157 interventional studies, 175 across the 38 observational. Of the 147 that completed or were terminated, 28 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 196 have an industry lead sponsor. The 10 most frequent:
Asger Lund, MD is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Asger Lund, MD has 4 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
11 of the studies in Diabetes Mellitus, Type 1 with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07247734Asger Lund, MDThe Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation | 2026-12-22 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
| NCT07172672University of AarhusThe TiMeD-T1D Project | 2027-02-01 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
Add all 11 to your calendar (.ics) → With an account.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to evaluate if colchicine in addition to standard of care improves markers of inflammation and cardiovascular disease in persons with type 1 diabetes. Participants will be assigned to either 0,5 mg colchicine daily or placebo in a 1:1 ratio for 26 weeks with the possibility of an additional 26 week extension of the intervention period. After the treatment period, there will a 5-year follow-up on all available outcome measures via electronic patient records for those who took part in the extension.
The current study aims to evaluate the efficacy of 0.5 mg colchicine once-daily added to existing standard of care in persons with established type 1 diabetes, existing arteriosclerotic cardiovascular disease (CVD) or at high risk thereof and C-reactive protein (CRP) ≥ 2 mg/L. Specifically, the primary objective is to determine the effect of colchicine (0.5 mg/daily) on levels of CRP (as assessed by high-sensitivity assays) as compared with placebo following 26-52 weeks of treatment. Additionally, the study will investigate the short and long-term effects of colchicine treatment on other markers of CVD and inflammation, markers of metabolism and markers of glycemic control in type 1 diabetes, including glycated hemoglobin (HbA1c), time spent in hypoglycemia (level 1 glucose readings 3.0-3.8 mmol/L and level 2 glucose readings \< 3.0 mmol/L), target glycemia (glucose readings 3.9-10 mmol/L) and hyperglycemia (level 1 glucose readings 10.1-13.9 mmol/L and level 2 glucose readings > 13.9 mmol/L) together with measures of glycemic variability evaluated by continuous glucose monitoring (CGM), insulin dosage, risk of hypoglycemia, risk of diabetic ketoacidosis and body weight. During the 5-year follow-up, we will collect all available outcome measures via electronic patient records.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Colchicine tablet 0.5 mg once-daily
Drug: Colchicine 0.5 MG Oral Tablet
Placebo tablet once-daily
Drug: Placebo
Colchicine 0.5 mg once-daily
Also known as: Colrefuz
Placebo tablet once-daily
Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of hemoglobin A1c (mmol/mol)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Time spent in target blood glucose range (3.9 - 10 mmol/L) evaluated by a continous glucose monitor (CGM)
(% of 24 hours)
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)
Time spent in hyperglycemia level 1 (10-13.9 mmol/L) evaluated by a continous glucose monitor (CGM)
(% of 24 hours)
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)
Time spent in hyperglycemia level 2 (> 13.9 mmol/L) evaluated by a continous glucose monitor (CGM)
(% of 24 hours)
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)
Time spent in hypoglycemia level 1 (3.0-3.8 mmol/L) evaluated by a continous glucose monitor (CGM)
(% of 24 hours)
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)
Time spent in hypoglycemia level 2 (< 3.0 mmol/L)evaluated by a continous glucose monitor (CGM)
(% of 24 hours)
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)
Insulin dosage
Number of units/day (both long- and short-acting insulin analogues)
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in body weight (kg)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in waist:hip ratio
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of low-density lipoprotein cholesterol (LDL) (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of interleukin (IL)-6 (pg/mL)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of tumor necrosis factor alpha (pg/mL)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Safety-related events
Serious adverse events (SAE), events of severe hypoglycemia, events of diabetic ketoacidosis
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of fibrinogen (µmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of serum amyloid A (mg/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of haptoglobin (g/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of interleukin (IL)-1β (pg/mL)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of interleukin (IL)-2 (pg/mL)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of intercellular adhesion molecule 1 (ICAM-1) (pg/mL)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of vascular cell adhesion molecule 1 (VCAM-1) (pg/mL)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of total leukocyte count, including neutrophil, lymphocyte, basophil and eosinophil counts (10^9/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in neutrophil:lymphocyte ratio
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of very low-density lipoprotein (VLDL) cholesterol (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of high-density lipoprotein (HDL) cholesterol (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of total cholesterol (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)
Change in fasting serum/plasma concentrations of triglycerides (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to week 56 (extension)
Change in fasting serum/plasma concentrations of lipoprotein (a) (mg/L)
%-point
Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to week 56 (extension)
Change in thrombocyte function measured by thromboelastography
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in fasting serum/plasma concentrations of N-terminal pro-brain natriuretic peptide (pro-BNP) (pmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in consultation blood pressure (mmHg)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in heart rate (beats/minute)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of albumin (g/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in urine albumin-to-creatinine ratio (mg/g)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 56 (extension)
Change left ventricular (LV) mass index evaluated by cardiovascular ultrasonography (g/m^2)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change left ventricular (LV) septal wall thickness evaluated by cardiovascular ultrasonography (mm)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change left ventricular (LV) posterior wall thickness evaluated by cardiovascular ultrasonography (mm)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change left ventricular (LV) ejection fraction (LVEF) evaluated by cardiovascular ultrasonography (%)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E) to peak velocity flow in late diastole caused by atrial contraction (A) (E/A ratio) evaluated by cardiovascular ultrasonography
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change early diastolic mitral inflow velocity (e') evaluated by cardiovascular ultrasonography (m/sec)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change ratio of early diastolic mitral inflow velocity (e') to early diastolic mitral annulus velocity (E) (E/e' ratio) evaluated by cardiovascular ultrasonography
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change ratio of early mitral inflow velocity (E) to global diastolic strain rate (e' sr) (E/e'sr ratio) evaluated by cardiovascular ultrasonography
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change left atrial volume (LAVi) evaluated by cardiovascular ultrasonography (mL)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change global longitudinal strain (GLS) evaluated by cardiovascular ultrasonography (%)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change aortic distensibility evaluated by cardiovascular ultrasonography (mmHg^-1)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change aortic strain evaluated by cardiovascular ultrasonography (%)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment)
Change in mean glucose evaluated by a continous glucose monitor (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in standard deviation evaluated by a continous glucose monitor (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in coefficient of variance evaluated by a continous glucose monitor (> 0.36 defined as glycemic variability)
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in glycemic variability (continuous overall net glycemic action (CONGA)) evaluated by a continous glucose monitor
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in mean amplitude of glycemic excursion evaluated by a continous glucose monitor
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in diabetes treatment satisfactory questionnaire, status version (DTSQs) (From 0 (min) to 6 (max), higher scores indicate a better outcome )
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in diabetes treatment satisfactory questionnaire, change version (DTSQc) (From -3 (min) to 3 (max), higher scores indicate a better outcome)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in audit of diabetes-dependent quality of life questionnaire (ADDQoL) (From -9 (min) to 9 (max), higher scores indicate a better outcome )
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of ketones (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Adverse events
As reported by participants
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in liver fat content as per the CAP score (dB/m) measured by FibroScan®
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in liver fibrosis score (kPa) measured by FibroScan®
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in fibrosis-4 (FIB-4) score (numerical scale, higher scores indicate a higher risk of fibrosis)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fatty liver index (FLI) score (numerical scale, higher scores indicate a higher risk of fibrosis)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of hemoglobin (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of thrombocytes (10^9/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of glucose (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of potassium (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of sodium (mmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of creatinine (umol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of alanine aminotransferase (U/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of aspartate aminotransferase (U/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of bilirubin (umol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of amylase (units/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of creatine kinase (U/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of C-peptide (pmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of glucagon (pmol/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of C-terminal telopeptide (ng/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in fasting serum/plasma concentrations of procollagen type 1 N-terminal propeptide (ng/L)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in body composition by bioimpedance analysis
%-point (fat free mass, total fat mass, muscle mass, bone mass)
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)
Change in body mass index (kg/m^2)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in waist circumference (cm)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in hip circumference (cm)
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in waist:hip ratio
%-point
Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)
Change in interleukin messenger ribonucleic acid (mRNA) expression measured by quantitative polymerase chain reaction
%-point
Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 56 (extension)
Plan to share: Yes — The study protocol has previously been published [DOI: 10.1111/dom.70139]. De-identified individual participant data will be available from publication of this article indefinitely upon request to the corresponding author from researchers who provide a methodologically sound proposal. To gain access to the data, the researchers will need to sign a data sharing agreement and/or collaborative agreement.
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Jan 2031, 88 months after the start.
Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 88 months is above that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Asger Lund, MD